Barrier. 2.1.1 Barrier will provide Abbott with [**] kg of GMP-quality Drug Substance (as Itraconazole) and [**] kg of GMP-quality HPMC free of charge together with a Certificate of Analysis and any information on drug handling, safety and relevant ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. toxicolgical data for Drug Substance (at least MSDS) which Abbott has not previously received. 2.1.2 Barrier will perform the analytical testing necessary to release the Bulk Product for further processing. 2.1.3 Barrier will perform milling and tabletting of the Bulk Product to manufacture the Finished Product applicable for clinical trial supply. 2.1.4 Barrier will perform the final release of the clinical trial samples.
Appears in 1 contract
Sources: Development and Supply Agreement (Barrier Therapeutics Inc)
Barrier. 2.1.1 Barrier will provide Abbott with [**] kg of GMP-quality Drug Substance (as Itraconazole) and [**] kg of GMP-quality HPMC free of charge together with a Certificate of Analysis and any information on drug handling, safety and relevant ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. toxicolgical data for Drug Substance (at least MSDS) which Abbott has not previously received.
2.1.2 Barrier will perform ▇▇▇▇▇▇m the analytical testing necessary to release the Bulk Product for further processing.
2.1.3 Barrier will perform milling and tabletting of the Bulk Product to manufacture the Finished Product applicable for clinical trial supply.
2.1.4 Barrier will perform the final release of the clinical trial samples.
Appears in 1 contract
Sources: Development and Supply Agreement (Barrier Therapeutics Inc)